Research Study on Multiple Myeloma (Kahler Disease) - Pipeline Review, H1 2016

Multiple Myeloma (Kahler Disease) - Pipeline Review, H1 2016 ​is a new market research publication announced by Reportstack. provides an overview of the Multiple Myeloma (Kahler Disease) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Multiple Myeloma (Kahler Disease), complete with analysis by stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Multiple Myeloma (Kahler Disease) and features dormant and discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Complete report available @ ​Multiple Myeloma (Kahler Disease) - Pipeline Review, H1 2016.

Scope

- The report provides a snapshot of the global therapeutic landscape of Multiple Myeloma (Kahler Disease)
- The report reviews pipeline therapeutics for Multiple Myeloma (Kahler Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Multiple Myeloma (Kahler Disease)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Multiple Myeloma (Kahler Disease)
- Identify potential new clients or partners in the target demographic

Companies Mentioned

4SC AG AB Science SA AbbVie Inc. Ablynx NV Acceleron Pharma, Inc. Acetylon Pharmaceuticals, Inc. Actinium Pharmaceuticals, Inc. Active Biotech AB Adaptimmune Therapeutics Plc Aduro BioTech, Inc. Affimed GmbH AIMM Therapeutics B.V. Altor BioScience Corporation Amgen Inc. Anthera Pharmaceuticals‚ Inc. APIM Therapeutics AS APO-T B.V. Arcarios BV Arno Therapeutics, Inc. Array BioPharma Inc. Arvinas, Inc. Asana BioSciences, LLC Astellas Pharma Inc. Astex Pharmaceuticals, Inc. Atara Biotherapeutics, Inc. Aurigene Discovery Technologies Limited Bellicum Pharmaceuticals, Inc. BioInvent International AB Biotest AG bluebird bio, Inc. Boehringer Ingelheim GmbH Boston Biomedical, Inc. Bristol-Myers Squibb Company Calithera Biosciences, Inc. Celgene Corporation Cell Source, Inc. etc.

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###